Press Review

Key Takeaways Stanford’s new wearable device using subtle audio cues to support focus and reduce anxiety in people with ADHD leads today’s Press Review for 8 December 2025. The roundup highlights research-driven tools, from vitamin D supplementation to AI automation,…

Key Takeaways A new AI app for customized ADHD task management leads today’s ADHD news and research, highlighting practical ways technology and self-care can reduce overwhelm. For 7 December 2025, the press review explores recent findings on screen usage, exercise,…

Key Takeaways Top story: Centanafadine demonstrates significant improvement in ADHD symptoms with a low risk of abuse. Vitamin D combined with methylphenidate safely and effectively reduces symptoms in children. AI productivity tool launches, tailored for neurodivergent professionals. Studies indicate preschoolers…

Key Takeaways Top story: New research identifies overlapping brain patterns behind ADHD and autism symptoms. FDA review considers centanafadine as a potential new treatment for ADHD. AI-powered digital tools are expanding access to personalized ADHD support. Recent findings highlight early…

Key Takeaways On 2 December 2025, ADHD medication news is led by Queensland’s move to expand access via specialist GPs, effective 1 December, aiming to smooth treatment pathways. New Zealand allocates funds to generic ADHD medication to address ongoing supply…

Key Takeaways A major global study confirms that combining medication with cognitive-behavioral therapy delivers the most effective outcomes for ADHD. This sets the focus for the ADHD press review on 29 November 2025. The review covers new treatments, technological innovations,…

Key Takeaways Top story: Landmark research confirms medication and cognitive behavioral therapy (CBT) as the most effective interventions for ADHD management. Adult ADHD medication shortages reveal critical gaps in treatment access for many individuals. AI-powered application launches to help neurodivergent…

Key Takeaways Top story: Evidence confirms medication and CBT as the most effective ADHD management options to date. New AI productivity app launches, built specifically with neurodivergent workflows in mind. Research reveals a correlation between increased screen time and small…

Key Takeaways Otsuka has submitted a triple reuptake inhibitor for ADHD treatment across all age groups, leading today’s Press Review for 26 November 2025 and setting the pace in ADHD news and developments 2025. The roundup highlights significant intersections between…

Key Takeaways New research links rare genetic variants to ADHD, providing insights into neurodivergence and potential treatment options. Scientists have identified rare genetic variants with a strong association to ADHD, deepening the understanding of ADHD neurodivergence research. Online ADHD assessment…